Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Sponsor
Innovaderm Research Inc.
Study ID
NCT05499416
Phase
PHASE4
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bimekizumab — DRUG
    Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16

Study Details

This is an open-label study to evaluate the effects of bimekizumab in patients with psoriasis vulgaris and who also have active psoriatic arthritis (PsA).

Key Dates

Start date
Jan 31, 2023
Status verified
Mar 2023
Primary completion
Sep 30, 2023
Completion
Apr 30, 2024

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab 320 mg SC injections
    Bimekizumab 320 mg solution administered via SC injections every 4 weeks for 16 weeks.

Primary Outcome Measure

Physician Global Assessment (PGA) x Body Surface Area (BSA) [ Time Frame: Week 24 ]

Related Studies